摘要
Background: Tumor growth rate (TGR), denoted as percentage change in tumor size per month, is a well-established indicator of tumor growth kinetics. The predictive value of early on-treatment TGR (EOT-TGR) for immunotherapy remains unclear. We sought to establish and validate the association of EOT-TGR with treatment outcomes in patients with advanced non-small-cell lung cancer (aNSCLC) undergoing anti-PD-1/PD-L1 (programmed cell death protein 1/programmed death-ligand 1) therapy. @@@ Patients and methods: This bicenter retrospective cohort study included a training cohort, a contemporaneously treated internal validation cohort, and an external validation cohort. Computed tomography images were retrieved to calculate EOT-TGR, denoted as tumor burden change per month during a period between baseline and the first imaging evaluation after immunotherapy. Kaplan-Meier methodology and Cox regression analysis were conducted for survival analyses. @@@ Results: In the pooled cohort (n = 172), 125 patients (72.7%) were males; median age at diagnosis was 58 (range 28-79) years. Based on the training cohort, we determined the optimal cut-off value for EOT-TGR as 10.4%/month. Higher EOT-TGR was significantly associated with inferior overall survival [OS; hazard ratio (HR) 2.93, 95% confidence interval (CI) 1.47-5.83; P = 0.002], worse progression-free survival (PFS; HR 2.44, 95% CI 1.46-4.08; P = 0.001), and lower objective response rate (3.3% versus 20.9%; P = 0.040) and durable clinical benefit rate (6.7% versus 41.9%; P 0.001). Results were reproducible in the two validation cohorts for OS and PFS. Among 43 patients who had a best response of progressive disease in the training cohort, those with high EOT-TGR had worse OS (HR 2.64; P = .041) and were more likely to progress due to target lesions at the first tumor evaluation (85.2% versus 0.0%; P <0.001). @@@ Conclusions: Higher EOT-TGR was associated with inferior OS and immunotherapeutic response in patients with aNSCLC undergoing anti-PD-1/PD-L1 therapy. This easy-to-calculate radiologic biomarker may help evaluate the abilities of immunotherapy to prolong survival and assist in tailoring patients' management.
学科与关键词
- Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective studyYang, Xiongwen; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Hu, Hao*; Huang, Jian*; Huang, Shaohong*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231206282.
- Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapyLeung, Elaine Lai-Han*; Li, Run-Ze; Fan, Xing-Xing; Wang, Lily Yan; Wang, Yan; Jiang, Zebo; Huang, Jumin; Pan, Hu-Dan; Fan, Yue; Xu, Hongmei; Wang, Feng; Rui, Haopeng; Wong, Piu; Sumatoh, Hermi; Fehlings, Michael; Nardin, Alessandra; Gavine, Paul; Zhou, Longen; Cao, Yabing*; Liu, Liang*Nature Communications, 2023, 14(1).被引 1
- Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter studyLiu, Shuai; Zhao, Liuyuan; Zhou, Guohua*Frontiers in Genetics, 2022, 13: 1016085.被引 1
